Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 300 versus RENO 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 300 versus RENO 30.
IOPAMIDOL-300 vs RENO-30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic, water-soluble iodinated contrast agent that attenuates X-rays, thereby enhancing radiographic visualization of vascular structures and organs. It does not bind to receptors and has no significant pharmacological activity.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures.
Intravenous or intra-arterial administration; dose varies by procedure (e.g., 1-2 mL/kg for CT, up to 50-100 mL for angiography) up to a maximum of 200 mL per procedure.
Adults: 30 mL (30 g iodine) intravenously as a single dose for imaging procedures; may repeat once if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function (creatinine clearance >90 mL/min). In moderate renal impairment it extends to 3-5 hours; in severe renal impairment (CrCl <30 mL/min) it can exceed 30 hours, prolonging diagnostic window.
Terminal half-life: 1-2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Primarily renal excretion of intact drug via glomerular filtration; >90% excreted unchanged in urine within 24 hours. Less than 1% fecal or biliary elimination.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent